Figure 1 Efficacy of anti-human GCGR antibody drug crotedumab in B-ob/ob mice

Efficacy of the anti-human GCGR antibody drug crotedumab (synthesized in-house) in B-ob/ob mice. Male B-ob/ob mice, 8-10 weeks old, were randomly assigned to 2 groups of 6-7 animals each. Crotedumab dosing occurred on Day 0. Non-fasting blood glucose was measured on days 0, 3, and 7, and fasting blood glucose was measured after 6 hours of fasting. A) Body weight changes in B-ob/ob mice. B-C) Non-fasting blood glucose and fasting blood glucose measurements.  (D) Crotedumab effect on glucose tolerance. E) Area under the curve of blood glucose content. Mice were fasted for 6 h with unlimited access to water, after which fasting blood glucose was measured at the tail tip (0 min).  Subsequently, glucose was injected intraperitoneally at 2 g/kg, and blood glucose was measured at the indicated times. (Fig. F-G) glucagon and insulin measurements. The results showed that crotedumab had hypoglycemic effects in both fasting and non-fasting conditions, and improved glucose tolerance in B-ob/ob mice. (Data are mean ± SEM; P ≤ 0.05, P ≤ 0.01, P ≤ 0.001)